Researcher Sigrid S. Skånland has been appointed project group leader in the group of Kjetil Taskén at the Department of Cancer Immunology, Institute for Cancer Research.
Her research group will focus on developing functional precision medicine for haematological cancers, in particular the B-cell malignancy chronic lymphocytic leukemia (CLL). By performing functional analyses including ex vivo drug sensitivity screening and single cell signaling analyses, her aim is to identify biomarker signatures that can predict treatment outcomes for the individual patient.
Sigrid S. Skånland received her PhD from the Faculty of Mathematics and Natural Sciences at University of Oslo in 2009, under the supervision of Prof. Kirsten Sandvig. She was then awarded with a long-term EMBO fellowship to do her post-doctoral training in the Molecular Signaling Group of Prof. Ivan Dikic (2009-2011) at the University Hospital Frankfurt, Germany. From 2011, Skånland has been affiliated with the research group of Prof. Kjetil Taskén, first at the Nordic EMBL Partnership for Molecular Medicine in Norway (NCMM), and since 2018 at Oslo University Hospital.
In 2020, Skånland was awarded a prestigious European Commission ERA PerMed research grant on tailoring the targeted treatment of chronic lymphocytic leukemia.